Research Plan
What makes ALS TDI so different from other biotech companies and research labs? Our unique and comprehensive approach leverages more than a decade
of treatment-focused ALS research and applies it on an industrial
scale to get therapeutics to today's ALS patients as quickly, efficiently, and cost-effectively as
possible. Our research team evaluates the most promising therapeutic hypotheses through the lenses of
the richest ALS research databases in the world. Treatments of all kinds are considered and tested
rigorously and rapidly.
Dr. Steve Perrin, CEO frequently speaks about our research plan to patients, families, industry executives and
academics worldwide.
"Introduction to ALS Research" by Dr. Steve Perrin (CEO/CSO)
This 60 minute presentation outlines the basic tenants of our research plan found in the above white
paper. He also highlights some recent and exciting research as well as current partnerships. We use
real work examples to illustrate some of the unique aspects of the drug development process from target
identification to clinical trials.
Click here to watch.
Overview of ALS TDI
This is an expanded version of the above presentation and is intended as a gateway into understanding
the basics to drug development through the lens of a non-profit biotech. Includes an overview of the
preclinical pipeline, clinical trials and current online resources for patients, caregivers and
families as well as pharma executives, neurologists and international researchers.
Click here to read more.
Interested in knowing more about who we are currently partnered with?
Click here.
The ALS TDI team works around the clock trying to do what many think impossible.
Click here to meet our "superheroes".